ExaGrid Reports Record Bookings and Revenue for Q4-2019 and Fiscal Year 2019
7.1.2020 16:00:00 EET | Business Wire | Press release
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup with data deduplication, today announced record bookings and revenue for Q4-2019 ending in December as well as a record fiscal year 2019. ExaGrid had significant growth in the Americas, Latin America, EMEA and APAC.
“This was our best quarter and fiscal year for bookings and revenue to date,” said Bill Andrews, CEO and President of ExaGrid. “We added over 100 new customers with a record number of new customer six-figure purchase orders. We achieved double-digit growth over the same quarter a year ago. ExaGrid focuses on organizations that need to store hundreds of terabytes to petabytes of backup data.”
Partner and Product Highlights in Q4-2019
- ExaGrid continued its strong sales growth with mid-market to enterprise organizations that use Veeam® Software, Commvault®, Veritas® NetBackup, Oracle RMAN Direct and other enterprise backup applications.
- ExaGrid had a record quarter for backup storage behind Commvault® due in part to an announcement made earlier in the year about ExaGrid’s ability to further deduplicate Commvault deduplicated data. ExaGrid does not require any change to the Commvault configuration and can improve backup efficiency by a factor of 3X.
- ExaGrid announced a new data storage solution for Acronis® Cyber Backup which provides efficient edge data protection and storage for remote sites.
- ExaGrid was voted “Backup Storage Innovation of the Year” at Storage, Digitalisation + Cloud (SDC) Awards 2019.
ExaGrid solves the three inherent compute problems to achieve faster backups, restores, and VM boots by leveraging its unique Landing Zone, adaptive deduplication, and scale-out architecture.
“First-generation deduplication solutions can be cost prohibitive for backup storage and are slow for backups, restores, and VM boots, which is why a high percentage of ExaGrid’s newly-acquired customers are replacing Dell EMC Data Domain, HPE StoreOnce, and the Veritas NetBackup 5200/5300 series of appliances. We are replacing low cost primary storage disk behind Commvault, as ExaGrid is far less expensive than Dell, HPE Nimble, NTAP eSeries and Cisco 3260, when customers require longer term retention,” Andrews said. “We continue to see growth behind Commvault, Veeam and Veritas NetBackup as the company moves up market.”
All backup storage vendors reduce storage and bandwidth to varying degrees, but most provide slow ingest rates due to deduplication being performed ‘inline.’ Additionally, other solutions only store deduplicated data, which causes restore speeds and VM boots to be very slow. ExaGrid’s ingest rate is 6X faster than its closest competitor. Unlike the first-generation vendors that only add capacity as data grows, ExaGrid appliances add compute with capacity, ensuring that the backup window remains fixed in length. Only ExaGrid uses a scale-out architecture with a unique Landing Zone, which holistically addresses all of the scalability and performance challenges of backup storage.
ExaGrid’s turnkey disk-based backup system combines enterprise storage with zone-level data deduplication, delivering a disk-based solution that is far more cost effective than low cost disk. Unlike first-generation inline/scale-up deduplication solutions that were either built into a backup application media server or into a dedicated storage appliance, ExaGrid delivers the backup industry’s only true Landing Zone and scale-out architecture with data deduplication. Utilizing ExaGrid’s Landing Zone with adaptive deduplication typically halves the cost of the first-generation large brand solutions and is 3X the backup performance and 20X the restore/VM boot performance. By using a scale-out architecture, ExaGrid is the only solution that keeps the backup window fixed in length as data grows and eliminates both forklift upgrades and forced product obsolescence.
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique Landing Zone, and
scale-out architecture. ExaGrid’s Landing Zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com or
connect with us on LinkedIn.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup in our customer
success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005250/en/
Contact information
Media Contact:
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872
x0248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
